Abstract
Introduction: While immunosuppressive therapy has positively impacted the prognosis of systemic lupus erythematosus (SLE), many patients still do not respond to traditional therapy. Thus, active SLE disease remains a significant problem. Furthermore, conventional immunosuppressive treatments for SLE are associated a high risk of side effects. These issues call for improvement in our current therapeutic armamentarium.Areas covered: In this review, the authors highlight the recent developments in therapies for SLE, and present an overview of drugs which are in early clinical development for SLE. There are many new therapeutic approaches being developed, including those focused on B-cell targets, T-cell downregulation, co-stimulatory blockade, anti-cytokine agents, and kinase inhibition, and Toll-like receptor inhibition. They also discuss peptide therapy as a potential method to re-establish immune tolerance, and some of the challenges ahead in developing and testing novel agents for SLE.Expert opinion: Many novel agents are currently in development for SLE, but this encouraging news is tempered by several disappointments in clinical trials and provides a timely moment to reflect on the future of therapeutic development in SLE. It seems likely that biological heterogeneity between patients is a major contributor to difficulty in drug design in SLE.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 573-583 |
| Number of pages | 11 |
| Journal | Expert Opinion on Investigational Drugs |
| Volume | 25 |
| Issue number | 5 |
| DOIs | |
| State | Published - May 3 2016 |
Fingerprint
Keywords
- b cell
- cytokine
- Systemic lupus erythematosus
- t cell
ASJC Scopus subject areas
- Pharmacology
- Pharmacology (medical)
Cite this
Drugs in early clinical development for Systemic Lupus Erythematosus. / Postal, Mariana; Sinicato, Nailú Angélica; Appenzeller, Simone; Niewold, Timothy B.
In: Expert Opinion on Investigational Drugs, Vol. 25, No. 5, 03.05.2016, p. 573-583.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Drugs in early clinical development for Systemic Lupus Erythematosus
AU - Postal, Mariana
AU - Sinicato, Nailú Angélica
AU - Appenzeller, Simone
AU - Niewold, Timothy B.
PY - 2016/5/3
Y1 - 2016/5/3
N2 - Introduction: While immunosuppressive therapy has positively impacted the prognosis of systemic lupus erythematosus (SLE), many patients still do not respond to traditional therapy. Thus, active SLE disease remains a significant problem. Furthermore, conventional immunosuppressive treatments for SLE are associated a high risk of side effects. These issues call for improvement in our current therapeutic armamentarium.Areas covered: In this review, the authors highlight the recent developments in therapies for SLE, and present an overview of drugs which are in early clinical development for SLE. There are many new therapeutic approaches being developed, including those focused on B-cell targets, T-cell downregulation, co-stimulatory blockade, anti-cytokine agents, and kinase inhibition, and Toll-like receptor inhibition. They also discuss peptide therapy as a potential method to re-establish immune tolerance, and some of the challenges ahead in developing and testing novel agents for SLE.Expert opinion: Many novel agents are currently in development for SLE, but this encouraging news is tempered by several disappointments in clinical trials and provides a timely moment to reflect on the future of therapeutic development in SLE. It seems likely that biological heterogeneity between patients is a major contributor to difficulty in drug design in SLE.
AB - Introduction: While immunosuppressive therapy has positively impacted the prognosis of systemic lupus erythematosus (SLE), many patients still do not respond to traditional therapy. Thus, active SLE disease remains a significant problem. Furthermore, conventional immunosuppressive treatments for SLE are associated a high risk of side effects. These issues call for improvement in our current therapeutic armamentarium.Areas covered: In this review, the authors highlight the recent developments in therapies for SLE, and present an overview of drugs which are in early clinical development for SLE. There are many new therapeutic approaches being developed, including those focused on B-cell targets, T-cell downregulation, co-stimulatory blockade, anti-cytokine agents, and kinase inhibition, and Toll-like receptor inhibition. They also discuss peptide therapy as a potential method to re-establish immune tolerance, and some of the challenges ahead in developing and testing novel agents for SLE.Expert opinion: Many novel agents are currently in development for SLE, but this encouraging news is tempered by several disappointments in clinical trials and provides a timely moment to reflect on the future of therapeutic development in SLE. It seems likely that biological heterogeneity between patients is a major contributor to difficulty in drug design in SLE.
KW - b cell
KW - cytokine
KW - Systemic lupus erythematosus
KW - t cell
UR - http://www.scopus.com/inward/record.url?scp=84964040067&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84964040067&partnerID=8YFLogxK
U2 - 10.1517/13543784.2016.1162291
DO - 10.1517/13543784.2016.1162291
M3 - Article
C2 - 26950689
AN - SCOPUS:84964040067
VL - 25
SP - 573
EP - 583
JO - Current Opinion in Investigational Drugs
JF - Current Opinion in Investigational Drugs
SN - 1354-3784
IS - 5
ER -